Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap - PubMed
6 hours ago
- #weight regain
- #obesity management
- #GLP-1 therapy
- GLP-1-based therapies lead to significant weight loss but discontinuing them often results in rapid weight regain and loss of cardiometabolic benefits within a year.
- Weight regain after stopping treatment reflects disease recurrence, reinforcing obesity as a chronic, relapsing condition, not therapeutic failure.
- Discontinuing therapy allows weight-defense mechanisms to re-emerge, pushing the body back toward its pre-treatment set point.
- A key clinical risk post-discontinuation is sarcopenic obesity, where fat mass recovers more than lean mass.
- Mitigation strategies include resistance training, structured tapering, and long-term maintenance care for chronic obesity management.